Dogwood Therapeutics reports 2025 results & clinical data

Dogwood Therapeutics (NASDAQ:DWTX) reported its fourth-quarter and full-year 2025 financial results, highlighting a pivot toward late-stage clinical development for its lead analgesic candidate, Halneuron®.

The company reported a net loss of $35.5 million, or $7.13 per share, for the 2025 fiscal year, driven largely by a surge in research and development expenses.

R&D spending reached $21.8 million for the year, a sharp increase from the $3.5 million recorded in 2024.

This capital deployment focused on the ongoing Phase 2b clinical trial, which has now recruited 143 patients and is more than 50% enrolled.

An interim analysis of a 97-patient subset demonstrated that Halneuron® effectively separated from the placebo, providing a positive signal for the trial’s primary objectives.

Management expects to report top-line data from the full study in the third quarter of 2026.

To support its clinical timeline, Dogwood recently fortified its balance sheet.

While the company ended 2025 with $6.5 million in cash, it successfully completed a financing agreement in January 2026 for up to $26.9 million.

The initial closing provided $12.5 million in gross proceeds ($11.4 million net).

Under the current operational plan, the company anticipates its cash reserves will fund operations into the fourth quarter of 2026, covering the critical window for the Halneuron® data readout.

Halneuron®, a highly purified form of tetrodotoxin, is being developed as a non-opioid alternative for the treatment of severe chronic pain.